Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327740 | 1.00 | GRIN2B (0.52) | GRIN2BRECQLSLC1A5KMOSCN9A | |
| SCHEMBL2327736 | 1.00 | GRIN2B (0.52) | GRIN2BRECQLSLC1A5KMOSCN9A | |
| SCHEMBL16088877 | 0.88 | GRIN2B (0.52) | GRIN2BRECQLPYGL | |
| SCHEMBL2326788 | 0.83 | RECQL (0.47) | GRIN2BRECQL | |
| SCHEMBL2326792 | 0.83 | RECQL (0.47) | GRIN2BRECQL | |
| SCHEMBL12185099 | 0.81 | RECQL (0.50) | GRIN2BRECQL | |
| SCHEMBL1109099 | 0.81 | SLC6A2 (0.48) | GRIN2BKMOSCN9AROCK2 | |
| SCHEMBL16088880 | 0.79 | RECQL (0.44) | GRIN2BRECQL | |
| SCHEMBL17730781 | 0.79 | RECQL (0.68) | RECQL | |
| SCHEMBL17737721 | 0.79 | RECQL (0.68) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | HAMP, SERPINC1, PRSS8 | GRIN2B 3168/4885RECQL 1094/4885SLC1A5 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.